Compare Ascendis Pharma A/S (ASND) vs Ishares Msci Italy ETF (EWI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Ishares Msci Italy ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Ishares Msci Italy ETF trades at $60.59. Which is the better fit depends on your goals.
| ASND | EWI | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $277.18 | $61.14 |
52-Week Low | $163.32 | $47.32 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
EWI trades at $60.59, up 0.51% with a bullish technical signal from moving averages. The stock recently hit a 52-week high as improving industrial data and Italy's recovery narrative gain traction. A dividend of $1.17 is scheduled for June 2026. Technical indicators show strong momentum with support at $60 and resistance at $61.
Outlook remains positive given technical strength and European market momentum, though stagflationary conditions in Italy and ECB rate hikes present macroeconomic headwinds. The stock offers exposure to European cyclical recovery but faces risks from energy price volatility and geopolitical tensions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →
